Kiniksa Pharmaceuticals International annual total liabilities
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kiniksa Pharmaceuticals International Total Liabilities Growth & History (KNSA)
Kiniksa Pharmaceuticals International's total liabilities was $196.0M for fiscal 2025.
View full Kiniksa Pharmaceuticals International company overviewKiniksa Pharmaceuticals International annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $196.0M | $53.9M | +37.93% |
| 2024 | 2024-12-31 | $142.1M | $54.6M | +62.45% |
| 2023 | 2023-12-31 | $87.5M | $24.0M | +37.72% |
| 2022 | 2022-12-31 | $63.5M | $15.8M | +33.00% |
| 2021 | 2021-12-31 | $47.8M | $10.2M | +27.27% |
| 2020 | 2020-12-31 | $37.5M | $8.4M | +28.92% |
| 2019 | 2019-12-31 | $29.1M | −$13.6M | −31.82% |
| 2018 | 2018-12-31 | $42.7M | $25.3M | +144.97% |
| 2017 | 2017-12-31 | $17.4M | — | — |
Kiniksa Pharmaceuticals International quarterly total liabilities
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $242.0M | $75.8M | +45.63% |
| Q1 2026 | 2026-03-31 | $219.6M | $77.8M | +54.82% |
| Q4 2025 | 2025-12-31 | $196.0M | $53.9M | +37.93% |
| Q3 2025 | 2025-09-30 | $176.9M | $58.7M | +49.59% |
| Q2 2025 | 2025-06-30 | $166.1M | $58.8M | +54.79% |
| Q1 2025 | 2025-03-31 | $141.8M | $54.1M | +61.59% |
| Q4 2024 | 2024-12-31 | $142.1M | $54.6M | +62.45% |
| Q3 2024 | 2024-09-30 | $118.3M | $40.4M | +51.78% |
| Q2 2024 | 2024-06-30 | $107.3M | $34.7M | +47.69% |
| Q1 2024 | 2024-03-31 | $87.8M | $35.0M | +66.35% |
| Q4 2023 | 2023-12-31 | $87.5M | $24.0M | +37.72% |
| Q3 2023 | 2023-09-30 | $77.9M | $2.0M | +2.62% |
| Q2 2023 | 2023-06-30 | $72.7M | $15.6M | +27.32% |
| Q1 2023 | 2023-03-31 | $52.8M | −$12.0M | −18.47% |
| Q4 2022 | 2022-12-31 | $63.5M | $15.8M | +33.00% |
| Q3 2022 | 2022-09-30 | $75.9M | $37.1M | +95.68% |
| Q2 2022 | 2022-06-30 | $57.1M | $13.7M | +31.46% |
| Q1 2022 | 2022-03-31 | $64.7M | $24.3M | +59.96% |
| Q4 2021 | 2021-12-31 | $47.8M | $10.2M | +27.27% |
| Q3 2021 | 2021-09-30 | $38.8M | $12.9M | +49.83% |
| Q2 2021 | 2021-06-30 | $43.4M | $22.4M | +106.53% |
| Q1 2021 | 2021-03-31 | $40.5M | $20.2M | +99.58% |
| Q4 2020 | 2020-12-31 | $37.5M | $8.4M | +28.92% |
| Q3 2020 | 2020-09-30 | $25.9M | −$4.0M | −13.35% |
| Q2 2020 | 2020-06-30 | $21.0M | −$11.9M | −36.17% |
| Q1 2020 | 2020-03-31 | $20.3M | −$19.4M | −48.85% |
| Q4 2019 | 2019-12-31 | $29.1M | −$13.6M | −31.82% |
| Q3 2019 | 2019-09-30 | $29.9M | $1.7M | +6.05% |
| Q2 2019 | 2019-06-30 | $32.9M | $9.6M | +41.19% |
| Q1 2019 | 2019-03-31 | $39.6M | — | — |
| Q4 2018 | 2018-12-31 | $42.7M | $25.3M | +144.97% |
| Q3 2018 | 2018-09-30 | $28.2M | — | — |
| Q2 2018 | 2018-06-30 | $23.3M | — | — |
| Q4 2017 | 2017-12-31 | $17.4M | — | — |
Kiniksa Pharmaceuticals International total liabilities trends
Over the last five fiscal years, Kiniksa Pharmaceuticals International's total liabilities increased from $37.5M to $196.0M, a change of $158.5M. The latest reported quarter, Q2 2026, shows $242.0M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kiniksa Pharmaceuticals International source filings ↗